Want to see LFWD full AI Analyst Report?
LFWD Stock Chart & Stats
$6.79
-$0.33(-14.93%)
At close: 4:00 PM EST
$6.79
-$0.33(-14.93%)
Day’s Range― - ―
52-Week Range$4.14 - $10.98
Previous CloseN/A
Volume483.00K
Average Volume (3M)316.99K
Market Cap
$24.57M
Enterprise Value$8.64M
Total Cash (Recent Filing)$11.42M
Total Debt (Recent Filing)$8.81M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Aug 12, 2026EPS Estimate
-1.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-19.66
Shares Outstanding2,814,409
10 Day Avg. Volume318,606
30 Day Avg. Volume316,993
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit1.13
Enterprise Value/Ebitda-0.51
Forecast
1Y Price Target
$10.00Price Target Upside47.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$28.29M
Bulls Say, Bears Say
Bulls Say
ReWalk Sales & Reimbursement ExpansionSustained ReWalk unit growth combined with expanding payer coverage and broader distribution creates structurally higher addressable demand. Durable reimbursement relationships and international distribution reduce single-market reliance and improve long-term adoption and replacement cycles for device sales and recurring service revenue.
Improved Liquidity From Financing & AcquisitionA materially stronger cash position reduces immediate liquidity pressure, buys time to execute manufacturing transitions and backlog recovery, and lowers near-term insolvency risk. This funding supports operational stabilization and targeted investments without immediate reliance on revenue turning positive.
Pipeline & Product Diversification (Oratech)Acquiring Oratech diversifies the company beyond exoskeleton hardware into a therapeutic delivery platform and supports adjacent neurorehab opportunities. This strategic breadth reduces single-product concentration, offers new commercial pathways, and can create cross-selling and long-term R&D optionality.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow forces ongoing external financing, raising dilution and creditor risk. Without a consistent path to positive cash generation, operational plans and product investments are constrained and the company remains vulnerable to funding cycles and cost-of-capital shifts.
Eroded Balance-sheet CushionZero reported shareholders' equity signals minimal buffer against losses and reduces financial flexibility. With limited equity cushion, adverse operating swings or further write‑downs could trigger covenant stress, restrict borrowing capacity, and accelerate dilution through rescue financings.
Execution Risk & Margin PressureOperational disruptions (manufacturing transition and backlog) plus tariffs and FX created meaningful margin deterioration and volatile revenue recognition. Sustained execution issues or continued cost headwinds would impair scaling economics, delay profitability, and weaken durable gross margin sustainability.
Lifeward News
LFWD FAQ
What was Lifeward’s price range in the past 12 months?
Lifeward lowest stock price was $4.14 and its highest was $10.98 in the past 12 months.
What is Lifeward’s market cap?
Lifeward’s market cap is $24.57M.
When is Lifeward’s upcoming earnings report date?
Lifeward’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.
How were Lifeward’s earnings last quarter?
Lifeward released its earnings results on May 15, 2026. The company reported -$3.13 earnings per share for the quarter, missing the consensus estimate of -$1.18 by -$1.95.
Is Lifeward overvalued?
According to Wall Street analysts Lifeward’s price is currently Undervalued.
Does Lifeward pay dividends?
Lifeward does not currently pay dividends.
What is Lifeward’s EPS estimate?
Lifeward’s EPS estimate is -1.39.
How many shares outstanding does Lifeward have?
Lifeward has 2,814,409 shares outstanding.
What happened to Lifeward’s price movement after its last earnings report?
Lifeward reported an EPS of -$3.13 in its last earnings report, missing expectations of -$1.18. Following the earnings report the stock price went up 1.592%.
Which hedge fund is a major shareholder of Lifeward?
Currently, no hedge funds are holding shares in LFWD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lifeward
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living with spinal cord injuries (SCI), granting them the ability to stand, walk, pivot, and navigate staircases by providing assistive hip and knee motion. Key offerings from the company include the ReWalk Exo-Suit and the ReWalk Personal 6.0. Founded by Amit Goffer on June 20, 2001, the enterprise maintains its corporate headquarters in Marlborough, Massachusetts.
LFWD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.View all LFWD earnings summariesLFWD Stock 12 Month Forecast
Average Price Target
$10.00
▲(47.28% Upside)
Technical Analysis
Ownership Overview
29.44% Insiders
<0.01% Mutual Funds
― Other Institutional Investors
70.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---